Bladder Preservation in Octogenarians With Invasive Bladder Cancer

被引:14
|
作者
Wehrberger, Clemens [1 ]
Berger, Ingrid [1 ]
Marszalek, Martin [1 ]
Ponholzer, Anton [1 ]
Wehrberger, Marlies [1 ]
Rauchenwald, Michael [1 ]
Madersbacher, Stephan [1 ]
机构
[1] Donauspital, Dept Urol & Androl, A-1220 Vienna, Austria
关键词
RADICAL CYSTECTOMY; TRANSURETHRAL RESECTION; ELDERLY-PATIENTS; CARCINOMA; SURVIVAL; EXPERIENCE; MORTALITY; YOUNGER;
D O I
10.1016/j.urology.2009.10.027
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES To analyze mortality and morbidity of octogenarians with newly diagnosed invasive transitional cell cancer (TCC) of the bladder who were managed without cystectomy. METHODS Retrospective chart review of all patients with newly diagnosed invasive TCC (>= pT1) in the period of 1997-2007, who were 80 years or older at diagnosis. RESULTS A total of 71 patients (86 + 4 years, mean + standard deviation [SD], pT1: n = 29; >pT2: n = 42) entered this analysis. In this geriatric population, treatment regimens were highly individualized. After transurethral resection, 61% of pT1-patients received bacillus Calmette-Guerin and 62% of those with >pT2-tumors external beam radiation. Mean overall survival (OS) of the entire cohort (n = 71) was 22 + 26 months for pT1-patients 34 + 33 versus 14 + 15 months for those with >pT2-tumors (P = .001). Mean cancer-specific survival was 58 months for pT1-patients and 11 months for >= pT2-patients (P < .001). OS was correlated to tumor stage and the degree of mobility, to a lesser extent to the American Society of Anesthesiologists (ASA) score, and only marginally to chronologic age. Satisfactorily bladder function was preserved in 73%. pT1-patients spent 16% of their remaining life-span in the hospital compared with 23% for patients with >pT2-tumors. CONCLUSIONS OS in TCC is dependent on tumor stage, age, mobility, and comorbidities, and a risk-stratified management is necessary. Patients with pT1G3 tumor and low ASA score have satisfying OS with bladder preservation, but in patients with >= pT2 and ASA 3-4 the prognosis is very bad. It remains questionable whether patients with tumor stages >= pT2 and ASA 1-2 despite high age would benefit from radical cystectomy. UROLOGY 75: 370-375, 2010. (C) 2010 Elsevier Inc.
引用
收藏
页码:370 / 375
页数:6
相关论文
共 50 条
  • [41] Survival after cystectomy for invasive bladder cancer
    de Vries, R. R.
    Nieuwenhuijzen, J. A.
    Vincent, A.
    van Tinteren, H.
    Horenblas, S.
    EJSO, 2010, 36 (03): : 292 - 297
  • [42] Selective organ preservation in muscle-invasive bladder cancer: Review of the literature
    Khosravi-Shahi, Parham
    Cabezon-Gutierrez, Luis
    SURGICAL ONCOLOGY-OXFORD, 2012, 21 (01): : E17 - E22
  • [43] Organ preservation by chemoradiation for bladder cancer
    Durdux, C.
    Fabiano, E.
    Mejean, A.
    CANCER RADIOTHERAPIE, 2019, 23 (6-7): : 732 - 736
  • [44] Bladder preservation in older adults with muscle-invasive bladder cancer: A retrospective study with concurrent chemotherapy and twice-daily hypofractionated radiotherapy schedule
    Alati, Aurelia
    Fabiano, Emmanuelle
    Geiss, Romain
    Mareau, Alexis
    Charles-Nelson, Anais
    Bibault, Jean-Emmanuel
    Giraud, Philippe
    Kreps, Sarah
    Mejean, Arnaud
    Housset, Martin
    Durdux, Catherine
    JOURNAL OF GERIATRIC ONCOLOGY, 2022, 13 (07) : 978 - 986
  • [45] Treating octogenarians with muscle-invasive bladder cancer: Preoperative opportunities for increasing the benefits of surgical intervention
    Bassett, Jeffrey C.
    Chang, Sam S.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (01) : 37.e13 - 37.e16
  • [46] Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience
    Efstathiou, Jason A.
    Spiegel, Daphna Y.
    Shipley, William U.
    Heney, Niall M.
    Kaufman, Donald S.
    Niemierko, Andrzej
    Coen, John J.
    Skowronski, Rafi Y.
    Paly, Jonathan J.
    McGovern, Francis J.
    Zietman, Anthony L.
    EUROPEAN UROLOGY, 2012, 61 (04) : 705 - 711
  • [47] Is The Cancer Genome Atlas (TCGA) bladder cancer cohort representative of invasive bladder cancer?
    Seiler, Roland
    Black, Peter C.
    Thalmann, George
    Stenzl, Arnulf
    Todenhoefer, Tilman
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (07) : 458.e1 - 458.e7
  • [48] Beyond surgery: bladder preservation and the role of systemic treatment in localised muscle-invasive bladder cancer
    Swinton, Martin
    Devi, Aarani
    Song, Yee Pei
    Hoskin, Peter
    Choudhury, Ananya
    WORLD JOURNAL OF UROLOGY, 2024, 42 (01)
  • [49] Bladder Preservation Therapy Conducted by Intra-arterial Chemotherapy and Radiotherapy for Muscle Invasive Bladder Cancer
    Hashine, Katsuyoshi
    Kusuhara, Yoshito
    Miura, Noriyoshi
    Shirato, Akitomi
    Sumiyoshi, Yoshiteru
    Kataoka, Masaaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (06) : 381 - 386
  • [50] The Effect of Tri-Modality Therapy with Bladder Preservation for Selective Muscle-Invasive Bladder Cancer
    Zhang Zhiyu
    Zhou Qi
    Song Zhen
    Ouyang Jun
    Zhang Jianglei
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2021, 20